Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certification & Accreditation
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Features
AMS Features
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Analysis of utilization, cost and prescription trends of mycophenolate mofetil and methotrexate among medicare patients
By
- AMS
posted
Jul 15, 2021 05:53 AM
0
Recommend
.
0 comments
0 views
Related Content
Mycophenolate mofetil and lichen planopilaris: systematic review and meta-analysis
- AMS
Added Apr 24, 2020
Blog Entry
Utilization and cost of bexarotene in the Medicare population: 2013 to 2017
- AMS
Added Aug 27, 2021
Blog Entry
Trends in Medicare utilization and reimbursement for wound debridement procedures 2012–2017
- AMS
Added Aug 14, 2020
Blog Entry
Assessment of dermatologist–patient gender concordance among medicare beneficiaries
- AMS
Added Jul 17, 2020
Blog Entry
Mycophenolate mofetil and mycophenolic acid for the treatment of eosinophilic fasciitis: report of two cases and literature review
- AMS
Added Feb 22, 2021
Blog Entry
Permalink
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic